Stroke patients who only received standard treatment showed no significant changes in blood markers related to oxidative stress over the first 24 hours of treatment.
Scientific Claim
In the control group receiving only standard stroke treatment, there were no significant changes in oxidative stress biomarkers (catalase, paraoxonase, TAC, MDA, neopterin, TOS) between baseline and 24 hours after treatment.
Original Statement
“There was no significant difference between the studied parameters before and after receiving the standard treatment in control group: TACcontrol/before = 3227.79 ± 192.53 versus TACcontrol/after = 3281 ± 279.37 (P = 0.82), TOScontrol/before = 74 ± 9.10 versus TOScontrol/after = 71.49 ± 8 (P = 0.83), MDAcontrol/before = 11.84 ± 1.26 versus MDAcontrol/after = 11.49 ± 6.23 (P = 0.78), Catalasecontrol/before = 4.87 ± 1.22 versus Catalasecontrol/after = 7.60 ± 1.38 (P = 0.14), Paraoxonasecontrol/before = 21.97 ± 1.61 versus Paraoxonasecontrol/after = 20.75 ± 1.38 (P = 0.55), and Neopterincontrol/before = 2.02 ± 0.56 versus Neopterincontrol/after = 0.97 ± 0.14 (P = 0.06).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The RCT design supports the conclusion that standard treatment alone did not significantly change biomarkers. The verb 'did not significantly change' is appropriate for this finding.
Evidence from Studies
Supporting (1)
Investigation of the effect of N-acetylcysteine on serum levels of oxidative inflammatory biomarkers in patients with stroke